Coherus Oncology, Inc. splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Toripalimab at $40.8 million, 97% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
51
|
42
|
26
|
257
|
211
|
327
|
476
|
356
|
0
|
2
|
190
|
| Product |
—
|
—
|
—
|
—
|
—
|
327
-31.4%
share 100.0%
|
476
+33.6%
share 100.0%
|
356
share 100.0%
|
—
|
—
|
—
|
| Udenyca |
—
|
—
|
206
+62.1%
share 780.4%
|
127
-37.7%
share 49.4%
|
204
share 96.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Toripalimab |
49
+59.6%
share 96.1%
|
41
+113.5%
share 96.8%
|
19
+3353.2%
share 72.5%
|
1
share 0.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Cimerli |
—
|
—
|
27
-78.4%
share 102.6%
|
125
+1705.2%
share 48.7%
|
7
share 3.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Yusimry |
—
|
—
|
8
+111.0%
share 28.6%
|
4
share 1.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| License And Service |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2
share 100.0%
|
—
|
| Product And Service Other |
2
+103.8%
share 3.9%
|
1
-81.6%
share 3.2%
|
7
+993.1%
share 27.5%
|
1
+135.5%
share 0.3%
|
0
+571.4%
share 0.1%
|
0
share 0.0%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CHRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1512762
- Former names
- Coherus BioSciences, Inc. (until May 28, 2025); BioGenerics, Inc. (until Jan 3, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.